XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.2
Subsequent Events
6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Deconsolidation of Veracyte SAS

On July 16, 2025, the Marseille Commercial Court published a decision approving the divestiture of certain portions of the Company's French subsidiary, Veracyte SAS, to Helio Diagnostics SAS, effective August 1, 2025. The remaining assets will be managed and controlled by the judicial administrator until such time that the Marseille Commercial Court appoints a judicial liquidator to solely initiate and manage liquidation proceedings. Effective August 1, 2025, the Company no longer has the power to control the financial and operating policies of Veracyte SAS. Accordingly, the Company will derecognize the related assets and liabilities from its consolidated financial statements in the three months ending September 30, 2025.

U.S. Income Tax

On July 4, 2025, the U.S. government enacted the One Big Beautiful Bill Act, or OBBBA, which includes numerous changes to existing tax law including extending or making permanent certain business and international tax measures initially established under the 2017 Tax Cuts and Jobs Act, which were set to expire. The OBBBA permanently eliminates the requirement to capitalize and amortize U.S.-based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred. The OBBBA also permanently extends the full expensing of qualifying assets through accelerated bonus depreciation in the period acquired. The OBBBA has multiple effective dates, with certain provisions effective in 2025 and others to be implemented through 2027. The Company will continue to analyze the OBBBA and its impact on its financial statements and will reflect any impact in the period of enactment.